Ongoing larger-scale studies in preterm infants, having lung development and BPD as main outcomes (ClinTrials registration NCT03253263) will help to clarify how IGF-1 supplementation may increase or decrease sensitivity to bacterial and viral infections. The gene discussed is IGF1; the disease is bronchopulmonary dysplasia.